Undisclosed TROP2-TRACTr / Janux Therapeutics - LARVOL DELTA

Janux Therapeutics Secures $35M Milestone Payment From BMY Deal (TradingView) - "The candidate is a tumor-activated therapy developed using Janux’s TRACTr platform, targeting an undisclosed antigen found across multiple solid tumors....In early 2026, JANX entered into a collaboration with BMY. Under the agreement, Janux will lead preclinical development through IND submission. BMY will hold the IND and take over subsequent clinical development and global commercialization of products arising from the collaboration. Janux will continue supporting the program through completion of the first phase I study."

Financing • Licensing / partnership • Solid Tumor

Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results (Businesswire) - "In the first half of 2022, Janux expects to submit an IND for its PSMA-TRACTr candidate, targeting prostate-specific membrane antigen (PSMA), for the treatment of metastatic castration-resistant prostate cancer (mCPRC)....In 2023, Janux expects to submit an IND application for its TROP2-TRACTr, targeting trophoblast cell surface antigen 2 (TROP2)."

IND • Genito-urinary Cancer • Oncology • Prostate Cancer

Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results (Businesswire) - "TRACTr product candidates advancing as planned: (i) In the first half of 2022, Janux expects to submit an Investigational New Drug (IND) application for its PSMA-TRACTr candidate, targeting prostate-specific membrane antigen (PSMA); (ii) In the second half of 2022, Janux expects to submit an IND application for its EGFR-TRACTr candidate, targeting epidermal growth factor receptor (EGFR); (iii) In 2023, Janux expects to submit an IND application for its TROP2-TRACTr, targeting trophoblast cell surface antigen 2 (TROP2)."

IND • Oncology